Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
{{output}}
Background: Targeted therapy prolongs the lives of men with metastatic castration-resistant prostate cancer (mCRPC) but mCRPC is ultimately lethal. DNA copy gains that amplify the Androgen Receptor (AR) gene locus are a key drive... ...
